We narrowed to 6,313 results for: pAAV

#100799-AAV1

Ready-to-use AAV1 particles produced from pAAV-TREtight-mTagBFP2-B19G (#100799). In addition to the viral particles, you will also receive purified pAAV-TREtight-mTagBFP2-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus; to be coinjected with pAAV-syn-FLEX-splitTVA-EGFP-tTA (Addgene# 100798). These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Liu et al Nature. 2017 Aug 31;548(7669):582-587. d

Dec. 18, 2018

Academic Institutions and Nonprofits only

#105678-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR1-FusionRed (#105678). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR1-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Sept. 24, 2020

Academic Institutions and Nonprofits only

#83900-AAV5

Ready-to-use AAV5 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 25, 2023

Academic Institutions and Nonprofits only

#128317-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-JRGECO1a (#128317). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-JRGECO1a plasmid DNA. EF1a-driven, Flp-dependent expression of the biosensor jRGECO1a. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

March 18, 2024

Academic Institutions and Nonprofits only

#83899-AAV9

Ready-to-use AAV9 particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 13, 2020

Academic Institutions and Nonprofits only

#45580-AAV1

Ready-to-use AAV1 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

Nirao Shah, Jim Wells

Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

Dec. 3, 2020

Academic Institutions and Nonprofits only

#75469-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-Flp-DOG-NW (#75469). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flp-DOG-NW plasmid DNA. EF1a-driven expression of Flp recombinase dependent on GFP (Flp-DOG); to be coinjected with GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Elife. 2016 May 20;5. pii: e15312. doi:

Feb. 19, 2020

Academic Institutions and Nonprofits only

#121675-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Dec. 15, 2020

Academic Institutions and Nonprofits only

#55641-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Aug. 28, 2020

Academic Institutions and Nonprofits only

#37825-AAV5.T

Ready-to-use AAV5 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

May 29, 2019

Academic Institutions and Nonprofits only

#107708-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin- soCoChR-GFP (#107708). In addition to the viral particles, you will also receive purified pAAV-hSynapsin- soCoChR-GFP plasmid DNA. Synapsin-driven somatic CoChR (soCoChR) fused to GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Nat Neurosci. 2017 Dec;20(12):1796-1806.

Sept. 7, 2018

Academic Institutions and Nonprofits only

#50465-AAV5.T

Ready-to-use AAV5 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

June 12, 2019

Academic Institutions and Nonprofits only

#37825-AAV6.T

Ready-to-use AAV6 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only

#37825-CAP-B22

Ready-to-use AAV CAP-B22 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the CAP-B22 serotype, which permits efficient transduction of neurons and astrocytes in the central nervous system. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Nov. 8, 2023

Academic Institutions and Nonprofits only

#135635-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#50477-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hM4D(Gi)-mCherry (#50477). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM4D(Gi)-mCherry plasmid DNA. CaMKIIa-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

March 12, 2021

Academic Institutions and Nonprofits only

#50474-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-hM3D(Gq)-mCherry (#50474). In addition to the viral particles, you will also receive purified pAAV-hSyn-hM3D(Gq)-mCherry plasmid DNA. hSyn-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Oct. 21, 2024

Academic Institutions and Nonprofits only

#50465-AAV9.T

Ready-to-use AAV9 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2019

Academic Institutions and Nonprofits only

#50465-AAV8.T

Ready-to-use AAV8 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2019

Academic Institutions and Nonprofits only

#112000-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-GCaMP6f (#112000). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6f plasmid DNA. Synapsin-driven, axon-targeted GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

March 12, 2021

Academic Institutions and Nonprofits only